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Abstract
Background: In a previous study we demonstrated the existence of numerical and functional
alterations of γδ T cells in healthy elderly. Recently, we analysed the involvement of γδ T
lymphocytes in malignant melanoma, describing a lower frequency of circulating γδ T cells, an
altered pattern of cytokine production, and an impaired in vitro expansion of these cells in primary
cutaneous melanoma patients.
Methods: In this study we investigated the existence of numerical and functional alterations of
circulating γδ T cells in young/adult and old melanoma patients, comparing the data obtained with
age-matched healthy subjects.
Results: We demonstrated that the number of circulating γδ+ T cells was significantly and similarly
reduced in young/adult and old melanoma patients and in old healthy subjects in comparison with
young healthy donors. The decrease was due to a reduction of Vδ2 T cells whereas the number of
Vδ1 T cells was not affected. A higher percentage of γδ+ T cells producing TNF-α was found in old
healthy donors, whereas a reduced number of TNF-α-producing  γδ+ T cells was present in
melanoma patients independently by age. No significant difference was observed in IFN-γ
production. After a 10-day in vitro culture, both the percentage and the expansion index of γδ T
cells, and in particular of Vδ2 subset, were significantly and similarly reduced both in young/adult
and old melanoma patients, and in healthy aged people, in comparison with young/adult healthy
subjects.
Conclusions: Our study demonstrates that the numerical and functional impairment of γδ T cells
found in melanoma patients is not correlated with age and that it has characteristics very similar to
the alterations of γδ T cells found in old healthy subjects. We suggest that a similar impairment of
γδ T cell population may be related to the increased susceptibility to tumors present in the elderly
as well as in the pathogenesis of malignant melanoma.
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Introduction
T lymphocytes bearing the γδ T cell receptor (TCR) repre-
sent a minor population of human peripheral lym-
phocytes (1–10%), the majority of them expressing the
CD3+CD4-CD8- phenotype [1-4]. The ability of γδ T cells
to respond to nonprocessed and nonpeptidic phosphoan-
tigens in a major histocompatibility complex (MHC)-
unrestricted manner is an important feature distinguish-
ing them from αβ T cells [5-9]. In human peripheral
blood two main populations of γδ T cells have been iden-
tified based on the TCR composition. The predominant
subset expresses the Vδ2 chain associated with Vγ9 and
represent 70% of the circulating γδ T cells in adults, while
a minor subset (approximately 30%) expresses a Vδ1-Jδ1
chain linked to a chain different from Vγ9. At birth the
Vδ1 population predominates, while in adults there is a
shift towards Vδ2 T lymphocytes, probably due to a selec-
tive response to environmental stimuli such as commonly
encountered bacteria. [10].
Although little is known about the physiologic signifi-
cance of γδ T cells, their marked reactivity toward myco-
bacterial and parasitic antigens as well as tumor cells
suggests that γδ T cells play a role in the anti-infectious
and anti-tumoral immune surveillance [11,4]. Few data
are available about the number and the function of γδ T
cells and of Vδ1 and Vδ2 subsets in aging. The complexity
of the gamma delta T cell repertoire has been found to
decrease with age as a consequence of the expansion of a
few T cell clones [12]. In our previous paper [11], we have
evaluated the role of γδ T cells from young, old, and cen-
tenarian subjects, demonstrating an age-dependent altera-
tion of γδ T lymphocytes, with a lower frequency of
circulating γδ T cells, an altered pattern of cytokine pro-
duction, and an impaired in vitro expansion of these cells.
We suggested a role of the γδ T cell impairment in the age-
related increase of infections and tumor diseases. Other
studies have showed the involvement of γδ T cells in the
immune defence against cancer either through a direct
reactivity against tumor cells, or because of their regula-
tory interactions with αβ T cells [13]. Recently, we
described an impairment of γδ T cell population in
patients with cutaneous primary melanomas, with a
decrease of their absolute number and percentage, an
altered cytokine production, and a reduced expansion of
γδ T cells, and particularly of the Vδ2 subset [14].
On the basis of the pivotal role that γδ T cells may have in
the elderly and in the immune response against
melanoma we tried to find out a possible correlation in
the alteration of γδ T cells between aged people and
melanoma patients. In this study we evaluated the periph-
eral representation, the in vitro expansion, and cytokine
production  γδ T cells from young/adult and old
melanoma patients, comparing the results with those
obtained in age-matched healthy controls.
Materials and Methods
Cell preparation and stimulation
Human peripheral blood was obtained from 9 young
(mean age ± SD, 42.3 ± 9.4 years; median: 41.0 years,
range 30–59), 12 old (71.8 ± 5.4 years; median 72.5 years,
range 60–80) melanoma patients, and 10 young (39.0 ±
5.7 years; median: 38.5, range 30–55), and 13 old (74.0 ±
2.0 years; median: 74.0 years, range 60–80) healthy
donors. Healthy subjects were volunteers in good and sta-
ble clinical conditions, and had laboratory parameters in
the physiological range. We excluded subjects in poor
health with degenerative diseases or in therapy with drugs
interfering with the immune system. Melanoma patients
have been admitted to the Dermatology Unit of the
I.N.R.C.A. Hospital of Ancona. Melanoma patients were
in good health other than for the existence of melanoma
as checked on the basis of clinical and laboratory param-
eters. The investigations were performed after approval by
a local institutional review board. A written informed con-
sent was obtained from each subject. Diagnosis of
melanoma was histologically confirmed. All patients
brought cutaneous primary non-metastatic melanoma
and were staged according to the new American Joint
Committee on Cancer staging system for cutaneous
melanoma [15]. A blood drawing was taken before the
surgical excision. Each donor was tested once and all the
tests were carried out with a single blood sample.
Fresh peripheral blood mononuclear cells (PBMC) were
fractionated on Ficoll-Paque (Pharmacia, Uppsala, Swe-
den) and separated by density gradient centrifugation
(400 g, 30 min). Cells from the interface of the gradients
were washed twice with Ca2+ and Mg2+- free phosphate
buffered saline (PBS, Gibco/Life Technologies, Gaithers-
burg, MD, USA) and resuspended in RPMI 1640 supple-
mented with 10% heat-inactivated fetal bovine serum,
penicillin (100 U/ml) and streptomycin (100 µg/ml) (all
from Life Technologies, complete medium) at a concen-
tration of 1.5 × 106/ml. Mononuclear cells were cultured
in the complete medium supplemented with 100 U/ml of
IL-2 (Chiron Italia, Milan, Italy). Phosphoantigen-specific
stimulation of γδ T cells was performed using the nonpep-
tidic antigen isopentenylpyrophosphate (30 µg/ml, IPP,
Sigma Chemical Co., St. Louis, MO, USA). The cells were
incubated at 37°C in an atmosphere of 95% air, 5% car-
bon dioxide, at 90% relative humidity in 24 well plates.
Monoclonal antibodies and FACS analysis
PBMCs were analysed for cell phenotype through double
staining with the following monoclonal antibodies
(mAbs): anti-CD3 (PE) and anti-pan γδ T cells (FITC), or
anti-TCR Vδ1 or anti-TCR Vδ2. The phycoerythrin (PE) -Immunity & Ageing 2005, 2:2 http://www.immunityageing.com/content/2/1/2
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conjugated monoclonal antibody anti-CD3 was pur-
chased from EuroClone (Devon, UK). The fluorescein iso-
thiocyanate (FITC) -conjugated anti-pan TCR γδ, anti-TCR
Vδ1, and anti-TCR Vδ2 were purchased from Endogen
(Boston, MA, USA). IgG1 (Becton Dickinson) was used as
isotype control.
0.5 × 106 PBMCs were washed in PBS containing 0,1%
NaN3 plus 5% FBS and labelled with 5 µl of anti-CD3 or
anti-TCR Vδ1 MoAbs or 2.5 µl of anti-pan TCR γδ or anti-
TCR Vδ2 for 30 min in ice. At the end of the incubation,
cells were washed in PBS containing 0,1% NaN3, resus-
pended in PBS (Gibco) and immediately analysed with a
Coulter XL flow cytometer.
Intracellular detection of IFN-γ and TNF-α
Mononuclear cells were stimulated with IPP and IL-2 for
18 h, and GolgiPlug (a protein transport inhibitor con-
taining brefeldin A, PharMingen, Milton Keynos, Eng-
land) was added during the last 12 h of culture to block
intracellular transport processes and allow cytokine accu-
mulation. 0.5 × 106 stimulated cells were stained with the
anti-pan TCR γδ mAb for 30 min at 4°C. Fixation-perme-
abilization of cells was performed in PBS/2% paraformal-
dehyde for 15 min at 4°C, followed by incubation for 30
min at room temperature in the dark with PE-conjugated
anti-human IFNγ mAb or anti-human TNF-α mAb diluted
in PBS, 1% BSA, and 0.05% saponin. Cells were finally
washed twice in PBS, 1% BSA, and 0.01 % saponin and
analysed on a XL flow cytometer (Coulter).
Expansion assay
PBMC were cultured for up to 10 days in the complete
medium supplemented with 100 U/ml of IL-2 and 30 µg/
ml of IPP to determine a phosphoantigen-specific stimu-
lation of γδ T cells. After 1 wk of culture, the volume cor-
responding to half the culture medium was replaced by
fresh medium. On day 10 of culture viable cells were
determined by trypan blue exclusion and used for FACS
analysis. The viability was always greater than 98% as
determined by trypan blue exclusion. The expansion of γδ
T cells was followed by cytometric analysis through dou-
ble staining of stimulated cells with anti-CD3 (PE) and
anti-pan γδ, or anti Vδ1, or anti Vδ2 T (FITC) mAbs. The
absolute number of γδ T cells in each culture was calcu-
lated as follow: (percentage of γδ T cells among total cells)
× (total cell count)/100. The γδ T cell expansion index was
then calculated by dividing the absolute number of γδ T
cells in stimulated cultures by the absolute number of γδ
T cells before culture [16].
Statistical analysis
Data were analysed for statistical significance by using
parametric or nonparametric tests according to the distri-
bution of the data. Comparisons of variables among
groups were made by one-way analysis of variance
(ANOVA) or Kruskal-Wallis one-way ANOVA on ranks.
When significant differences were found, the differences
among groups were made by the Student-Newman-Keuls
method or Dunn's method. Difference between means
was considered significant at the 5% level (P < 0.05). The
Table 1: Absolute number of γδ T cells, Vδ1 T cells, and Vδ2 T cells, in young/adult and old healthy subjects and melanoma patients.
Absolute number
Donors γδ T cells Vδ1 T cells Vδ2 T cells Vδ2/Vδ1 ratio
Healthy
Young/adult 115.2 ± 39.3a 38.0 ± 11.9 82.6 ± 34.0 2.2
Old 62.1 ± 28.7* 35.9 ± 11.7 37.7 ± 24.6* 1.0
Melanoma
Young/adult 74.5 ± 25.3* 31.9 ± 18.1 42.8 ± 9.8* 1.3
Old 52.9 ± 38.0* 20.6 ± 3.7 33.5 ± 31.2* 1.6
a Data are expressed as mean ± S.D. of the number of cells per mm3 in the peripheral blood.
*p at least <0.01 versus young/adult healthy subjectsImmunity & Ageing 2005, 2:2 http://www.immunityageing.com/content/2/1/2
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Percentage of γδ T cells in young/adult and old melanoma patients and age-matched healthy subjects Figure 1
Percentage of γδ T cells in young/adult and old melanoma patients and age-matched healthy subjects. Freshly isolated (A) or 10-
day cultured (B) PBMC from young/adult and old melanoma patients and young/adult and old healthy subjects were double 
stained with MoAb anti pan- γδ (FITC) and anti-CD3 (PE) and analyzed by flow cytometry. Statistical analyses was performed as 
reported in Mat. and Methods.Immunity & Ageing 2005, 2:2 http://www.immunityageing.com/content/2/1/2
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statistical analysis was performed with SigmaStat software
version 1.03 (Jandel Scientific, Germany).
Results
Ex vivo analysis of γδ T lymphocytes
Peripheral blood lymphocytes from 9 young/adult and 12
old melanoma patients and 10 young and 13 old healthy
subjects were analysed for the percentage and the absolute
number of γδ T cells through double staining with anti-
CD3 and anti-γδ mAbs. As shown in Table 1 the absolute
number of γδ T cells was significantly reduced in both
groups of melanoma patients and in healthy aged people
in comparison with young/adult healthy subjects (p <
.01). As shown in Fig. 1A, the ex vivo percentage of
CD3+γδ+ T cells in the peripheral blood was significantly
lower in melanoma patients than in healthy donors (p <
.01). As shown in Table 1, the absolute number of Vδ1 T
cells did not show significant difference in the four groups
of donors. Differently, the absolute number of Vδ2 T cells
was significantly reduced in both groups of melanoma
patients and in old healthy people in comparison with
young/adult healthy subjects (p < .0001). The Vδ2 and
Vδ1 subsets were differently represented in the four
groups: in young/adult healthy controls the Vδ2 subset
was predominant (Vδ2/Vδ1 ratio = 2.2) whereas in old
healthy donors and in young/adult and old melanoma
patients the Vδ2/Vδ1 ratio was progressively decreased.
Analysis of TNF-α production by γδ T cells in melanoma patients and age-matched healthy subjects Figure 2
Analysis of TNF-α production by γδ T cells in melanoma patients and age-matched healthy subjects. PBMC young/adult and old 
melanoma patients and young/adult and old healthy subjects were stimulated for 18 h in the presence of IPP (30 µg per ml) and 
IL-2 (100 U per ml). The last 12 h of culture were performed in the presence of GolgiPlug, a protein transport inhibitor con-
taining brefeldin. Single-cell analysis of TNF-α synthesis in γδ T cells from a representative subject for each group was per-
formed following dual staining with cell surface anti- γδ T (FITC) MoAb and intracellular anti- TNF-α (PE) MoAb. Number in 
brackets indicate the percentages of γδ T cells synthesizing TNF-α among total γδ T lymphocytes.Immunity & Ageing 2005, 2:2 http://www.immunityageing.com/content/2/1/2
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Cytokine production by γδ T lymphocytes
Since it has been demonstrated that activated γδ T cells
produce TNF-α and IFN-γ, we studied the intracellular
production of these cytokines in one-day stimulated γδ T
cells from healthy subjects and melanoma patients. As
shown in Fig. 2 the percentage of γδ T cells producing
TNF-α was significantly higher in old healthy controls in
comparison with young/adult healthy, and young/adult
and old melanoma patients (p < .05). The percentage of
γδ T cells producing IFN-γ was similar in young/adult and
old healthy subjects (mean ± SD, 17.9 ± 10.0 and 14.7 ±
8.9). In a similar way the percentage of γδ T cells produc-
ing IFN-γ did not show differences between young/adult
and old melanoma subjects (8.5 ± 4.9 and 8.1 ± 1.3) (data
not shown).
Expansion of γδ T lymphocytes
The expansion of γδ T cells was evaluated after 10 days of
culture in the presence of IPP and low dose interleukin-2
(IL-2). Both the proportion of γδ T cells, evidenced by
double staining FACS analysis, and their relative increase
in comparison with the γδ T cell number found on day 0
(expansion index), were evaluated. As shown in Fig. 1B,
the proportion of γδ T cells reached on day 10 was signif-
icantly lower in both groups of melanoma patients and in
old healthy subjects than in young/adult healthy donors
(p < .01). In a similar way, the expansion index of γδ T
cells after 10 days of in vitro culture was significantly
reduced in the same three groups mentioned above (p <
.05, Table 2). As shown in the same Table 2, the expansion
index of the Vδ2 subset was significantly lower in all
melanoma patients and in old healthy donors than in
young healthy donors (p < .03).
Discussion
We and others have demonstrated an impaired potential
of γδ T cells in aged people, as evidenced by the reduction
of the absolute number of circulating γδ T cells, in partic-
ular of the Vδ2 T subset, an altered pattern of cytokine pro-
duction, an impaired in vitro expansion of these cells, and
an increased expression of the early activation marker
CD69, in aged people in comparison with young subjects
[11,17,18]. Recently, studying a group of melanoma
patients ranging from young to old age (32–80 yr), we
described numerical and functional alterations of γδ T
cells from these subjects, once compared to healthy age-
matched donors [14]. In this study we have investigated
on whether the age-related impairment of circulating γδ T
cells is similar to the alteration found in melanoma
patients and if melanoma patients of advanced age have a
greater impairment of γδ T cells in comparison with
melanoma patients of younger age or with old healthy
donors. With these premises, we studied the peripheral
representation, in vitro expansion, and cytokine produc-
tion of γδ T lymphocytes from young/adult and old
patients with cutaneous primary melanoma comparing
the data obtained with age-matched healthy subjects.
We demonstrated that both the number of circulating γδ T
cells and their in vitro expansion were decreased in
melanoma patients and that the impairment did not cor-
relate with the age of patients. Young/adult and old
melanoma patients had a similar derangement of γδ T
cells, and this impairment had numerical and functional
characteristics like to those found in old healthy subjects.
This evidence stresses the relevant role that this lym-
phocyte population may exert, either directly or through
the regulation of T cell-mediated specific responses [11],
both in the elderly and in melanoma patients.
The reduction of γδ T cell number well correlated with the
decrease of the Vδ2 T cell subset, i.e., the most frequent
subset of circulating γδ T cells [2,4]. The Vδ2 population is
involved in the reactivity toward microbial antigens and
tumor cell antigens [4,19]. The role of Vδ2 T cells in the
immune defence against cancer has been demonstrated
on the basis of their reactivity against certain lymphoma
cells, such as Daudi cells [20], and for their presence
among tumor infiltrating lymphocytes in various cancer
types [21]. Not only the number but also the function of
γδ T cells was altered in melanoma patients as well as in
old healthy subjects. The in vitro expansion of γδ T cells,
that represent one of the most relevant functional param-
eters for γδ T cells, was significantly reduced in young/
adult and old melanoma patients, and in old healthy
donors.
Under normal conditions, γδ T cells respond to antigen
challenge by secreting large quantities of TNF-α and IFN-
Table 2: Expansion index of γδ T cells and Vδ2 T cells in healthy 
subjects and melanoma patients
Expansion Indexa
Donors γδ T cells Vδ2 T cells
Healthy
Young/adult 13.1 ± 8.8b 7.1 ± 4.5
Old 4.6 ± 3.5* 3.1 ± 2.0*
Melanoma
Young/adult 3.8 ± 2.6* 4.6 ± 0.2*
Old 2.0 ± 1.8* 0.9 ± 0.4*
a The expansion index was calculated by dividing the absolute number 
of γδ T cells in stimulated cultures by the absolute number of γδ T 
cells before culture.
bData are expressed as mean ± S.D.
*p at least <0.05 versus young/adult healthy subjectsPublish with BioMed Central    and   every 
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γ [16,21] which contribute to the activation of both spe-
cific and aspecific immune responses. In aged subjects we
found an increased production of TNF-α by γδ T cells [11].
In this study, we show that the percentage of γδ T cells pro-
ducing TNF-α was significantly reduced in young/adult
and old melanoma patients in comparison with age-
matched healthy subjects. Probably, the pro-inflamma-
tory state which has been described in old ages [22], may
represent a stimulus for the production of TNF-α in γδ T
cells from aged subjects, differently with what occurs in
old melanoma patients.
In conclusion, we demonstrate that the numerical and
functional derangement of γδ T cells which we have found
in melanoma patients, is not correlated with age of
donors, and that old patients with cutaneous primary
melanoma have an impairment of γδ T cells similar to that
found in old healthy subjects. This evidence suggests a
link between γδ T cell deterioration and the low protection
against infections and tumor diseases present in the eld-
erly, as well as the inefficacious immune defense against
melanoma, both in young/adult and old ages.
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